Novavax price target lowered to $9 from $14 at TD Cowen
The Fly

Novavax price target lowered to $9 from $14 at TD Cowen

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone flu vaccine resuming plans to initiate Ph3 imminently. Q3 COVID vaccine revenues missed as expected, given delayed start as the low initial market share driving FY24 guidance down.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App